The Technical Analyst
Heron Therapeutics Inc [HRTX]
Exchange: NASDAQ Sector: Healthcare Industry: Biotechnology
Heron Therapeutics Inc Price, Forecast, Insider, Ratings, Fundamentals & Signals
Current Signal: SELL (auto-tracking)
-2.58% $2.64
America/New_York / 19 apr 2024 @ 16:00
| FUNDAMENTALS | |
|---|---|
| MarketCap: | 396.87 mill |
| EPS: | -0.800 |
| P/E: | -3.30 |
| Earnings Date: | May 08, 2024 |
| SharesOutstanding: | 150.33 mill |
| Avg Daily Volume: | 2.61 mill |
| RATING 2024-04-19 |
|---|
| B |
| Neutral |
| RATINGS | ||
|---|---|---|
| Rating CashFlow: | Strong Buy | |
| Return On Equity: | Strong Buy | |
| Return On Asset: | Sell | |
| DE: | Strong Sell | |
| P/E: | Sell | |
| Price To Book: | Strong Sell |
| QUARTER GROWTHS | ||||||
|---|---|---|---|---|---|---|
| 3/22 | 4/22 | 1/23 | 2/23 | 3/23 | 4/23 | |
| Revenue | ||||||
| Gr.Profit | ||||||
| Ebit | ||||||
| Asset | ||||||
| Debt |
| PE RATIO: COMPANY / SECTOR |
|---|
| 0.00x |
| Company: PE -3.30 | sector: PE -3.05 |
| PE RATIO: COMPANY / INDUSTRY |
|---|
| -0.56x |
| Company: PE -3.30 | industry: PE 5.88 |
| DISCOUNTED CASH FLOW VALUE |
|---|
| N/A |
| N/A |
| Expected Trading Range (DAY) |
|---|
|
$ 2.41 - 2.85 ( +/- 8.21%) |
| ATR Model: 14 days |
Insider Trading
| Date | Person | Action | Amount | type |
|---|---|---|---|---|
| 2024-04-19 | Duarte Ira | Buy | 3 874 | Common Stock |
| 2024-04-19 | Duarte Ira | Sell | 1 122 | Common Stock |
| 2024-04-19 | Duarte Ira | Sell | 3 874 | Restricted Stock Units |
| 2024-04-19 | Forbes William P | Buy | 3 874 | Common Stock |
| 2024-04-19 | Forbes William P | Sell | 3 874 | Restricted Stock Units |
| INSIDER POWER |
|---|
| 66.37 |
| Last 96 transactions |
| Buy: 15 032 989 | Sell: 3 241 807 |
Forecast:
16:00 - $2.63
Live Trading Signals (every 1 min)
Forecast
1: 16:00 - $2.63
Forecast 2: 16:00 - $2.63
Forecast 3: 16:00 - $2.63
SCORE
10.00
Buy
10.00
Buy
Score Algorithm Version: 1.2C
Last version updated: Fri April 15th, 2022
Last version updated: Fri April 15th, 2022
| Indicator Signals | |
|---|---|
| RSI 21 | |
| SMA | |
| Trend | |
| Trend 2 | |
| Trend 3 | |
| MACD |
| Volume Signals | |
|---|---|
| Price | $2.64 (-2.58% ) |
| Volume | 2.31 mill |
| Avg. Vol. | 2.61 mill |
| % of Avg. Vol | 88.52 % |
| Signal 1: | |
| Signal 2: |
Today
Last 12 Months
RSI
Last 10 Buy & Sell Signals For HRTX
0 Signals | Accuracy: 0.00% | Accuracy Buy: 0.00% | Accuracy Sell: 0.00%
Avg return buy: 0.00 % | Avg return sell: 0.00 %
$1 invested is now $1.00 or 0.00% since Coming Soon
| Date | Signal | @ | Closed | % | Feb 8 - 15:35 | sell | $2.33 | N/A | Active |
|---|
HRTX
Heron Therapeutics, Inc., a biotechnology company, engages in developing treatments to address unmet patient needs. The company's product candidates utilize its proprietary Biochronomer, a drug delivery technology, which delivers therapeutic levels of a range of short-acting pharmacological agents over a period from days to weeks with a single administration. It offers SUSTOL (granisetron), an extended-release injection for the prevention of acute and delayed nausea and vomiting associated with moderately emetogenic chemotherapy, or anthracycline and cyclophosphamide combination chemotherapy regimens; and CINVANTI, an intravenous formulation of aprepitant, a substance P/neurokinin-1 receptor antagonist for the prevention of acute and delayed nausea and vomiting associated with highly emetogenic cancer chemotherapy, as well as nausea and vomiting associated with moderately emetogenic cancer chemotherapy. The company is also developing ZYNRELEF, a dual-acting local anesthetic that delivers a fixed-dose combination of the local anesthetic bupivacaine and a low dose of the nonsteroidal anti-inflammatory drug meloxicam; HTX-019, an investigational agent for the prevention of postoperative nausea and vomiting; and HTX-034 for postoperative pain management, as well as is in Phase Ib/II clinical study in patients undergoing bunionectomy. The company was formerly known as A.P. Pharma, Inc. and changed its name to Heron Therapeutics, Inc. in January 2014. Heron Therapeutics, Inc. was founded in 1983 and is headquartered in San Diego, California.
Latest Press Releases
2024-04-11 16:05:00 - Press Release
Heron Therapeutics To Host Investor Day On May 15, 2024 In New York City
San diego , april 11, 2024 /prnewswire/ -- heron therapeutics, inc. (nasdaq: hrtx), a commercial-stage biotechnology company, today announced that it will host an investor day on wednesday, may 15, 2024 in new york city, beginning at 9:30 am et. the event will include presentations from members of the company's leadership team highlighting the renewed focus across the acute care and oncology franchises and panel discussions featuring patient and physician experience with heron's commercial products.
2024-03-28 16:05:00 - Press Release
Heron Therapeutics Announces Presentation At The 23rd Annual Needham Virtual Healthcare Conference
San diego , march 28, 2024 /prnewswire/ -- heron therapeutics, inc. (nasdaq: hrtx), a commercial-stage biotechnology company, today announced that craig collard, chief executive officer of heron, will participate in a fireside chat on wednesday, april 10, 2024, at 11:00 am et at the 23rd annual needham virtual healthcare conference. the conference is being held in a virtual format, april 8-11, 2024.
2024-03-12 16:05:00 - Press Release
Heron Therapeutics Announces Fourth Quarter And Full-year 2023 Financial Results And Highlights Recent Corporate Updates
2023 oncology care franchise revenue was $107.9 million, exceeding full-year 2023 guidance zynrelef® achieved quarterly record of $5.6 million in q4 net product sales ended 2023 with cash and cash equivalents of $80.4 million announced partnership with crosslink life sciences, llc to expand zynrelef promotional efforts on january 7, 2024 received fda approval for expanded indication of zynrelef on january 23, 2024 san diego , march 12, 2024 /prnewswire/ -- heron therapeutics, inc. (nasdaq: hrtx) ("heron" or the "company"), a commercial-stage biotechnology company, today announced financial results for the three and twelve months ended december 31, 2023 and highlighted recent corporate updates...
2024-01-23 20:00:00 - Press Release
Heron Therapeutics Announces Fda Approval Of Zynrelef® Indication Expansion To Include Additional Orthopedic And Soft Tissue Procedures
– expanded indication for zynrelef now covers approximately 13 million procedures annually – san diego , jan. 23, 2024 /prnewswire/ -- heron therapeutics, inc. (nasdaq: hrtx), a commercial-stage biotechnology company, today announced that the u.s. food and drug administration (the "fda") has approved its supplemental new drug application ("nda") for zynrelef® (bupivacaine and meloxicam) extended-release solution to expand the indication for soft tissue and orthopedic surgical procedures including foot and ankle, and other procedures in which direct exposure to articular cartilage is avoided. zynrelef was previously approved for foot and ankle, small-to-medium open abdominal, and lower extremity total joint arthroplasty surgical procedures in adults.
2024-01-07 17:00:00 - Press Release
Heron Therapeutics Announces Partnership With Crosslink Life Sciences To Expand Promotional Effort For Zynrelef®, The First And Only Non-opioid Dual Acting Local Anesthetic For Post-operative Pain
San diego , jan. 7, 2024 /prnewswire/ -- heron therapeutics, inc. (nasdaq: hrtx), a commercial-stage biotechnology company, today announced that it has entered into a five-year distributor partnership with crosslink life sciences, llc to expand the sales network supporting zynrelef® (bupivacaine and meloxicam) extended-release solution. the partnership will launch in several phases, initially at a regional level, followed by an expanded national rollout.
Latest News
2024-03-12 22:35:08 - Seeking Alpha
Heron Therapeutics, Inc. (HRTX) Q4 2023 Earnings Call Transcript
2024-03-12 19:00:17 - Zacks Investment Research
Compared to Estimates, Heron Therapeutics (HRTX) Q4 Earnings: A Look at Key Metrics
Although the revenue and EPS for Heron Therapeutics (HRTX) give a sense of how its business performed in the quarter ended December 2023, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.
2024-03-07 10:16:05 - Zacks Investment Research
Curious about Heron Therapeutics (HRTX) Q4 Performance? Explore Wall Street Estimates for Key Metrics
Evaluate the expected performance of Heron Therapeutics (HRTX) for the quarter ended December 2023, looking beyond the conventional Wall Street top-and-bottom-line estimates and examining some of its key metrics for better insight.
2024-02-29 09:56:09 - Zacks Investment Research
5 Small Drug Stocks to Buy From a Rebounding Industry
Innovation is expected to continue to drive growth of the Medical-Drugs industry. UTHR, ESPR, HRTX, LYRA and ALDX may prove to be good additions to one's portfolio.
2024-02-17 01:54:45 - Seeking Alpha
Heron Therapeutics Is Out Of Survival Mode
Heron Therapeutics has made progress in shoring up its balance sheet and cutting expenses, improving its financial position. Revenue growth remains a challenge. The expanded label for Zynrelef and the partnership with CrossLink could help accelerate growth in 2024.
2024-02-06 13:01:05 - Zacks Investment Research
All You Need to Know About Heron Therapeutics (HRTX) Rating Upgrade to Strong Buy
Heron Therapeutics (HRTX) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #1 (Strong Buy).
2024-01-25 07:46:03 - Zacks Investment Research
Heron (HRTX) Gains 19% on FDA Nod for Zynrelef Label Expansion
Heron (HRTX) rises 19% on label expansion of its postoperative pain management drug, Zynrelef, to include additional orthopedic and soft tissue procedures.
2024-01-15 16:51:07 - InvestorPlace
The 3 Most Undervalued Biotech Stocks to Buy in January
Companies within the biotechnology industry are very interesting to investors because they see wild swings in share price following positive or negative news, particularly in the case of small biotech companies. Investing in biotech and other pharmaceutical stocks can be risky because their price action can be so swift and unpredictable.
2023-12-29 15:14:25 - Seeking Alpha
Heron Therapeutics Gets Back On Track
HRTX's Zynrelef sales are back on track, with potential for significant growth pending approval of a supplemental New Drug Application. Aponvie sales have been underwhelming thus far and probably won't contribute much to HRTX's revenues in the near term. HRTX's financials show a net loss in Q3'23, but the completion of restructuring brings optimism for future profitability.
2023-11-30 09:00:00 - Seeking Alpha
Why Heron Therapeutics Is A Compelling Buy Into 2024
Heron Therapeutics develops solutions for pain and discomfort associated with chemotherapy and surgery, with four FDA-approved products. The company underwent a leadership change and implemented a plan to improve efficiency and profitability. Zynrelef, an opioid alternative, has the potential to become one of Heron Therapeutics' main value drivers.